Work for Life Sciences Companies
BRG experts have worked with medical device companies and their national associations to address changes in federal regulations and the impact of such changes on their operations. This work has focused on changes in Medicare regulations and has included the preparation of responses to proposed regulations.
The California Institute for Regenerative Medicine enlisted BRG experts to develop an economic model to measure the impact of disease cures developed through stem cell research, which has been applied to a key investment made by the CIRM. The model can be used to measure the economic impact of medical research in several different settings.
BRG experts have also developed a model to measure the impact of the Affordable Care Act on the operations and revenues of life sciences companies. The model focuses on changes in Medicare and Medicaid requirements for drug purchases and rebates. The model has been applied for pharmaceutical manufacturers who have used it for strategic planning.